Clinical Trial

Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)

Study acronym: THOR
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, single arm, phase 2 trial enrolling patients with untreated Extensive-Stage Small-Cell Lung Cancer (ES SCLC), with a strong translational attitude.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-11-11; most recent amendment 2025-06-18.
Status change: Not Yet Recruiting → Recruiting 2023-05-11
Trial Details
NCT Number NCT05623319
Lead Sponsor Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Collaborators: Merck Sharp & Dohme LLC
Conditions SCLC,Extensive Stage
Enrollment 60 participants
Start Date 2023-03-27
Primary Completion 2027-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2025-06-24